Table 4. Primary outcome All studies; cessation and reduction of at least 90%.

Study name	Intervention	Total N	Event rate	Odds ratio with 95% CI and significance of global estimate
Frank et al. [2]	F3 Pheromone spray	17	0.18	0.86 [0.16–4.51]
Hunthausen [32]	F3 Pheromone spray	54	0.33	2.00 [0.58–6.86]
Ogata & Takeuchi [5]	F3 Pheromone spray	36	0.36	2.26 [0.62–8.21]
Mills and Mills [6]	F3 Pheromone diffuser	10	0.20	1.00 [0.15–6.67]
Dehasse [1]	Clomipramine	26	0.35	2.12 [0.54–8.26]
Landsberg & Wilson [33]	Clomipramine	25	0.68	8.50 [2.14–33.81]
King et al. [19]	Clomipramine	18	0.61	6.29 [1.48–26.76]
Hart et al. [21]	Clomipramine	6	0.33	2.00 [0.27–15.08]
Hart et al. [21]	Fluoxetine	16	0.69	8.80 [1.92–40.34]
Pryor et al. [18]	Fluoxetine	9	1.00	69.67 [3.37–1440.21]
Global estimate				3.16 [1.94–5.14] P<0.0001

Heterogeneity: P>0.10.